|
04 Oct 2019 |
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
|
|
04 Oct 2019 |
GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells
|
|
02 Oct 2019 |
Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Society
|
|
02 Oct 2019 |
NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Biologics
|
|
02 Oct 2019 |
Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
|
|
02 Oct 2019 |
Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T
|
|
01 Oct 2019 |
Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001
|
|
01 Oct 2019 |
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
|
|
01 Oct 2019 |
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
|
|
30 Sep 2019 |
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
|
|
30 Sep 2019 |
Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing
|
|
27 Sep 2019 |
BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU
|
|
27 Sep 2019 |
The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients
|
|
27 Sep 2019 |
First Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting B Cell-Activating Factor Receptor (BAFF-R) Eradicates Blood Cancers That Relapsed After CD19 CAR T Therapies
|
|
25 Sep 2019 |
Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
|
|
25 Sep 2019 |
Kadimastem Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS
|
|
25 Sep 2019 |
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio
|
|
24 Sep 2019 |
Topline Results of DPN Phase III Study
|
|
24 Sep 2019 |
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
|
|
24 Sep 2019 |
GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
|
|
22 Sep 2019 |
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies
|
|
18 Sep 2019 |
Procarta receives CARB-X award of up to $9.2 million
|
|
18 Sep 2019 |
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
|
|
18 Sep 2019 |
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
|
|
16 Sep 2019 |
Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy
|
